Liang Jinying, Bai Mengxin, Bi Yarong, Jian Xiangjie, Wang Siyan, Jiang Shang, Zhao Ying, Ma Weiwei, Yin Shaoping, Zhang Wenli
School of Pharmacy, Xinxiang Medical University, Xinxiang 453003, China; Xinxiang Key Laboratory for Epigenetic Molecular Pharmacology, Xinxiang 453003, China.
School of Pharmacy, Xinxiang Medical University, Xinxiang 453003, China; People's Hospital of Kaifeng, Kaifeng 475002, China.
J Control Release. 2025 Feb 10;378:103-115. doi: 10.1016/j.jconrel.2024.12.008. Epub 2024 Dec 11.
Due to the two major physiological barriers restricted by mucus penetration and epithelia transport, oral insulin therapy using nano-delivery system remains challenging. Heyndrickxia coagulans spores can survive the harsh conditions of gastrointestinal tract (GIT), and penetrate in the mucus through germination to probiotics with their amphipathic proteinaceous coat shedding in the gut epithelium, which makes it possible to be functionalized with hydrophilic peptide/protein and form nanoparticles (NPs) in vivo. Inspired by the natural physiological properties of spores, novel deoxycholic acid-modified Heyndrickxia coagulans spores loaded with insulin (DA-Spore/Ins) as the generators of autonomous bio-based nanoparticles were designed to solve these absorption barriers to enhance oral insulin delivery. The DA-Spore/Ins delivery system achieved preferable drug protection and rapid mucus penetration through its germination in the intestinal microenvironment. Meanwhile, DA-Spore/Ins NPs could be spontaneously formed by the self-assembly of the disintegrated DA-covalently amphipathic protein coat and the hydrophilic protein/peptides drug. This can efficiently transport through the epithelial cells through the bile acid pathway. In vivo studies indicated that DA-Spore/Ins delivery system achieved an oral relative bioavailability of 15.1 % and superior hypoglycemic effect in type I diabetic rats characterized by good biocompatibility. These studies suggested that the intrinsic biological characteristics of Heyndrickxia coagulans spore-based nanogenerators rendered their promising application in oral insulin or other protein drug therapy.
由于受到黏液渗透和上皮转运这两个主要生理屏障的限制,使用纳米递送系统进行口服胰岛素治疗仍然具有挑战性。凝结芽孢杆菌孢子能够在胃肠道的恶劣条件下存活,并通过萌发穿透黏液成为益生菌,其两亲性蛋白质外壳在肠道上皮中脱落,这使得它能够与亲水性肽/蛋白质功能化,并在体内形成纳米颗粒(NPs)。受孢子自然生理特性的启发,设计了新型载胰岛素的脱氧胆酸修饰凝结芽孢杆菌孢子(DA-孢子/胰岛素)作为自主生物基纳米颗粒的生成器,以解决这些吸收屏障,增强口服胰岛素递送。DA-孢子/胰岛素递送系统通过在肠道微环境中萌发实现了较好的药物保护和快速的黏液穿透。同时,DA-孢子/胰岛素纳米颗粒可由分解的DA-共价两亲性蛋白质外壳和亲水性蛋白质/肽药物自组装自发形成。这可以通过胆汁酸途径有效地穿过上皮细胞。体内研究表明,DA-孢子/胰岛素递送系统在I型糖尿病大鼠中实现了15.1%的口服相对生物利用度和优异的降血糖效果,且具有良好的生物相容性。这些研究表明,基于凝结芽孢杆菌孢子的纳米发生器的内在生物学特性使其在口服胰岛素或其他蛋白质药物治疗中具有广阔的应用前景。